Corpus ID: 33030077

Technology evaluation: HIVAC-1e.

@article{Zheng1999TechnologyEH,
  title={Technology evaluation: HIVAC-1e.},
  author={R. Zheng},
  journal={Current opinion in molecular therapeutics},
  year={1999},
  volume={1 1},
  pages={
          121-5
        }
}
  • R. Zheng
  • Published 1999
  • Medicine
  • Current opinion in molecular therapeutics
Bristol-Myers Squibb is developing a vaccine, HIVAC-1e, comprised of a recombinant vaccinia virus expressing the HIV-1 gp160 envelope glycoprotein. The vaccine has potential for the treatment of HIV and other viral infections and has entered phase I trials [135333]. In an initial phase I trial, 11 vaccinia-naïve volunteers were vaccinated with HIVAC-1e, followed by a booster with baculovirus-derived gp160 (VaxSyn). Two weeks after boosting, all 11 volunteers developed HIV-1 specific IgG, with… Expand
Vaccines for Viral and Parasitic Diseases Produced with Baculovirus Vectors
Vaccines for viral and parasitic diseases produced with baculovirus vectors.